Cargando…
The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users
BACKGROUND COVID-19 infection has led to a worldwide pandemic, and new cases are on the rise. Intravenous drug users (IVDU) are presumably at a higher risk of being infected since they have poor personal hygiene, live in groups, and have risky behaviors. The current study aimed to evaluate the serop...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iranian Association of Gastroerterology and Hepatology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531943/ https://www.ncbi.nlm.nih.gov/pubmed/34712441 http://dx.doi.org/10.34172/mejdd.2021.206 |
_version_ | 1784586972602302464 |
---|---|
author | Mohammadi, Zahra Eghtesad, Sareh Hashemi-Shahri, Seyed Mohammad Tabatabaei, Seyed Mehdi Sharafkhah, Maryam Poustchi, Hossein |
author_facet | Mohammadi, Zahra Eghtesad, Sareh Hashemi-Shahri, Seyed Mohammad Tabatabaei, Seyed Mehdi Sharafkhah, Maryam Poustchi, Hossein |
author_sort | Mohammadi, Zahra |
collection | PubMed |
description | BACKGROUND COVID-19 infection has led to a worldwide pandemic, and new cases are on the rise. Intravenous drug users (IVDU) are presumably at a higher risk of being infected since they have poor personal hygiene, live in groups, and have risky behaviors. The current study aimed to evaluate the seroprevalence of COVID-19 in IVDU in comparison with non-drug users (N-DU). METHODS This cross-sectional study was conducted on 167 IVDU and 134 N-DU. A questionnaire gathering data on demographics, comorbidities, and use of personal protective equipment was administered to all participants. In addition, 5 cc of blood was taken from each individual to test for SARS-CoV-2 specific antibodies (Pishtaz Teb SARS-Cov-2 ELISA kits). RESULTS The mean age of N-DU and IVDU were 38.9 ± 12.9 and 40.38 ± 10.24 years, respectively. COVID-19 seroprevalence in IVDU was 9.7%, and 4.8% in N-DU, but this finding was not statistically significant (p = 0.096). CONCLUSION While the seroprevalence of COVID-19 was not significantly different among the two groups, IVDU should still be considered by policymakers as a high-risk group due to their lifestyle and risky behaviors. Providing personal protective equipment and other means of protection and treatment to this population can help mitigate the spread of and mortality from COVID-19. |
format | Online Article Text |
id | pubmed-8531943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Iranian Association of Gastroerterology and Hepatology |
record_format | MEDLINE/PubMed |
spelling | pubmed-85319432021-10-27 The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users Mohammadi, Zahra Eghtesad, Sareh Hashemi-Shahri, Seyed Mohammad Tabatabaei, Seyed Mehdi Sharafkhah, Maryam Poustchi, Hossein Middle East J Dig Dis Brief Report BACKGROUND COVID-19 infection has led to a worldwide pandemic, and new cases are on the rise. Intravenous drug users (IVDU) are presumably at a higher risk of being infected since they have poor personal hygiene, live in groups, and have risky behaviors. The current study aimed to evaluate the seroprevalence of COVID-19 in IVDU in comparison with non-drug users (N-DU). METHODS This cross-sectional study was conducted on 167 IVDU and 134 N-DU. A questionnaire gathering data on demographics, comorbidities, and use of personal protective equipment was administered to all participants. In addition, 5 cc of blood was taken from each individual to test for SARS-CoV-2 specific antibodies (Pishtaz Teb SARS-Cov-2 ELISA kits). RESULTS The mean age of N-DU and IVDU were 38.9 ± 12.9 and 40.38 ± 10.24 years, respectively. COVID-19 seroprevalence in IVDU was 9.7%, and 4.8% in N-DU, but this finding was not statistically significant (p = 0.096). CONCLUSION While the seroprevalence of COVID-19 was not significantly different among the two groups, IVDU should still be considered by policymakers as a high-risk group due to their lifestyle and risky behaviors. Providing personal protective equipment and other means of protection and treatment to this population can help mitigate the spread of and mortality from COVID-19. Iranian Association of Gastroerterology and Hepatology 2021-01 2021-03-02 /pmc/articles/PMC8531943/ /pubmed/34712441 http://dx.doi.org/10.34172/mejdd.2021.206 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc/4.0/ This work is published by Middle East Journal of Digestive Diseaes as an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited. |
spellingShingle | Brief Report Mohammadi, Zahra Eghtesad, Sareh Hashemi-Shahri, Seyed Mohammad Tabatabaei, Seyed Mehdi Sharafkhah, Maryam Poustchi, Hossein The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users |
title | The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users |
title_full | The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users |
title_fullStr | The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users |
title_full_unstemmed | The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users |
title_short | The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users |
title_sort | seroprevalence of covid-19 in intravenous drug users in comparison to non-drug users |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531943/ https://www.ncbi.nlm.nih.gov/pubmed/34712441 http://dx.doi.org/10.34172/mejdd.2021.206 |
work_keys_str_mv | AT mohammadizahra theseroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers AT eghtesadsareh theseroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers AT hashemishahriseyedmohammad theseroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers AT tabatabaeiseyedmehdi theseroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers AT sharafkhahmaryam theseroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers AT poustchihossein theseroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers AT mohammadizahra seroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers AT eghtesadsareh seroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers AT hashemishahriseyedmohammad seroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers AT tabatabaeiseyedmehdi seroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers AT sharafkhahmaryam seroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers AT poustchihossein seroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers |